, Tracking Stock Market Picks
Enter Symbol:

up 240.00 %

IDERA PHARMACEUTICAL (IDRA) rated Overweight by Piper Jaffray

Posted on: Thursday,  Jan 3, 2013  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight IDERA PHARMACEUTICAL (NASDAQ: IDRA) on 01/03/2013, when the stock price was $0.85. Since
then, IDERA PHARMACEUTICAL has gained 240.00% as of 08/27/2015's recent price of $2.89.
If you would have followed this Piper Jaffray's recommendation on IDRA, you would have gained 240% of your investment in 966 days.

Idera Pharmaceuticals, Inc. (Idera) is a biotechnology company. The Company is engaged in the discovery and development of synthetic deoxyribonucleic acid (DNA)-and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. TLRs are specific receptors present in immune system cells that recognize the DNA or RNA of pathogens, such as bacteria or viruses and initiate an immune response. IMO-2125, a TLR9 agonist, is the Company lead drug candidate for infectious diseases. As part of the Company?s infectious disease program, it is also evaluating RNA-based compounds that act as agonists of TLR7 and TLR8.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/3/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  24.09 %
1 Month up  66.12 %
3 Months up  78.61 %
1 YTD up  263.52 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy